BioForm sees Q4 loss widen
This article was originally published in Clinica
Executive Summary
Medical aesthetics firm BioForm Medical was hit by an $11.2m one-time charge, related to its acquisition of Advanced Cosmetic Intervention in April 2008, which led to a four-fold increase in net loss for the fourth quarter. Increased operating costs from the expansion of its sales and marketing network, clinical programmes, and other general administrative expenses also contributed to the net loss, which widened from $4.9m to $20m. The San Mateo, California firm saw sales grow by 8% to $16.7m.
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.